Merck Faces Challenges as Keytruda Patent Expiration Looms
Merck cuts 2025 revenue guidance and misses key drug sales targets in Q3, while preparing for Keytruda patent expiration and navigating tariff threats and China vaccine issues.
/ 12 items
#MRK↓
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Pfizer Leads the Way on Drug Pricing and Domestic Investment
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
IO Biotech Restructuring After Cylembio BLA Rejection
IO Biotech won't submit its Cylembio cancer vaccine application after the FDA recommended against it due to trial results narrowly missing significance. IOBT will plan a new study and cut 50% of staff to save cash.
Evaxion Secures Landmark AI-Discovered Vaccine Deal with MSD
Evaxion secured a major licensing deal for its AI-discovered vaccine, EVX-B3, with Merck & Co. (MSD), potentially worth over $600 million and validating Evaxion's groundbreaking AI platform.
Merck's Cost Cuts: Keytruda Patent & Gardasil Woes
Merck initiates $3B annual cost cuts by 2027 due to Keytruda's 2028 patent expiry & a 55% Q2 drop in Gardasil sales from China. Reinvesting for post-Keytruda growth.